Background and Purpose-Visit-to-visit variability in blood pressure (vBP) is associated with ischemic stroke. We sought to determine whether such variability has genetic causes and whether genetic variants associated with BP variability are also associated with ischemic stroke.
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October 2013 F amilial studies have long provided evidence of heritability (31%-68%) of blood pressure (BP). 1 In recent years, substantial progress has also been made in our understanding of the genetics of various measures of BP (systolic BP [SBP] , diastolic BP, mean arterial pressure, and pulse pressure). [2] [3] [4] [5] [6] [7] However, episodic hypertension or variability in BP remains understudied, despite evidence supporting their role as risk factors in vascular events. 8 Visit-to-visit variability in SBP is a strong predictor of ischemic stroke independent of mean BP, 9 with hypertensives showing the most BP variability over a series of visits and having the greatest risk of a cardiovascular event. 8, 10 Determining whether BP variability has a genetic basis is difficult given the lack of prospective cohorts with visitto-visit BPs recorded and accompanying Genome Wide Association Study (GWAS) data. The Anglo-Scandinavian Cardiac Outcome Trial (ASCOT) study is a longitudinal study investigating the impact of a calcium channel blocker against a β-blocker regime in hypertensive individuals at moderate risk for a cardiovascular outcome recruited in the United Kingdom, Ireland, and Nordic countries from 1998 to 2000. 11 Long-term BP variability measurements spread >5 years, and genomewide genotyping was available for an ASCOT study subset, the ASCOT-United Kingdom-Ireland cohort (ASCOT-UK-IR), allowing a GWAS to be conducted for genetic risk variants of BP variability.
We hypothesized that because visit-to-visit BP variability is associated with the risk of ischemic stroke more than hemorrhagic stroke, 8 and because hypertension is a major modifiable risk factor, any genetic variants that are associated with BP variability may also be associated with ischemic stroke. On the basis of recently published GWAS 12, 13 that show the genetic risk of stroke to be subtype specific, we tested the genetic variant in ischemic stroke subtypes. In an effort to replicate our findings, we also tested the genetic variant for association with BP variability in an independent set of individuals from the ASCOT Scandinavian (ASCOT study recruited in Denmark, Finland, Norway, and Sweden [ASCOT-DK-FI-NO-SE]) cohort.
Materials and Methods

Study Populations
ASCOT
The ASCOT-Blood Pressure-Lowering Arm (ASCOT-BPLA) is an investigator-led multicenter trial that included >19 000 patients with hypertension, aged 40 to 79 years at baseline, with an average SBP of 140/90 mm Hg with treatment and 160/100 mm Hg without treatment. 11 Patients had no history of coronory heart disease, but had ≥3 other risk factors for cardiovascular disease, such as left ventricular hypertrophy, type II diabetes mellitus, peripheral artery disease, previous stroke/transient ischemic attack, men aged ≥55 years, or cigarette smoking. The study tested the impact of a contemporary calcium channel blocker-based regimen against an older β-blocker-based regime in hypertensives at moderate risk of a cardiovascular outcome. The primary objective of the BP-lowering arm was to assess and compare the long-term effects of 2 blood pressure-lowering regimens on the combined end point of nonfatal myocardial infarction (including silent myocardial infarction) and fatal coronory heart disease. BP was measured in a seated position by a uniform automated device (Omron HEM705CP) in all participants during an average of 13 visits across 5.5 years.
The ASCOT-UK-IR GWAS population included 3802 individuals extracted from the original cohort of 19 342 hypertensives. Visitto-visit BP variability measurements were recorded prospectively for within-visit and between-visit BP variability >5.5 years. Blood samples for DNA isolation were collected, of which 3802 individuals of European ancestry from United Kingdom and Ireland were genotyped, allowing a GWAS to be conducted for risk variants of BP variability. A subset of 3900 individuals from the ASCOT-DK-FI-NO-SE for whom DNA was available was used for replication analyses. The recruitment criterion for the Scandinavian ASCOT participants was identical to that for the United Kingdom and Irish participants, and all had BP measurements performed at similar time points to calculate BP variability. Details of ASCOT-UK-IR study population are tabulated in Table I in the online-only Data Supplement.
Ischemic Stroke
The stroke population included 8624 cases and 12 722 controls from 7 different cohorts (online-only Data Supplement): Australian Stroke Genetics Collaborative (ASGC), 13, 14 Bio-Repository of DNA in Stroke (BRAINS), 15, 16 Genetics of Early Onset Stroke (GEOS), 17, 18 Ischemic Stroke Genetics Study and Siblings with Ischemic Stroke Study (ISGS 19 /SWISS), 20 Welcome Trust Case Control Consortium 2-United Kingdom (WTCCC2-UK), 21 WTCCC2-Germany, 21 and Vitamin Intervention for Stroke Prevention (VISP) trial. 22 All participating cohorts received institutional ethical clearance and signed consent from each participating study subject. ISGS/SWISS, Genetics of Early Onset Stroke and, VISP used sex-and age-matched stroke-free controls recruited from the local population. Bio-Repository of DNA in Stroke and WTCCC2-UK used the WTCCC 1958 British Birth cohort and National Blood Service controls. WTCCC2-Germany derived controls of German Caucasian origin from the KORAgen study (www.gsf.de/kora).
Trial of Org 10172 in Acute Stroke Treatment classification 23 was performed by an in-house neurologist and all stroke cases were classified into 3 categories: cardioembolic stroke, large artery disease, and small vessel disease. All cohorts except VISP provided stroke subtype data.
Details of stroke cohort study populations are tabulated in Table II in the online-only Data Supplement.
Genotyping and Imputation
The genotyping, imputation, and quality control for the ASCOT GWAS has been described previously. 24 A detailed description of genotyping, imputation, and quality control methods for each participating study in the ischemic stroke analysis is provided in the Materials and Methods and Table III in the online-only Data Supplement. Single nucleotide polymorphism (SNP) genotyping of rs976683 in 3900 Scandinavian ASCOT samples was performed using the KASPAR assay at St. Bartholomew's Hospital and the London Genome Centre.
Image processing and genotype calling were performed using SDS (Applied Biosystems) and Autocaller (Applied Biosystems). Any genotypes with discrepancies between the 2 calling algorithms were manually inspected and corrected.
Data Analysis
In the ASCOT study, BP was measured in all participants during an average of 13 visits across 5.5 years. Measurements during the first 6 months after starting therapy were excluded because this was a period of forced medication titration and any differential medication effects could have acted as a confounder. Data simulations demonstrated that the combination of within-visit BP variability and visit-to-visit BP variability allowed the use of more BP measurements. Withinindividual visit-to-visit BP variability phenotype was expressed as mean (±SD) and coefficient of variation (SD/mean) using the second and third readings for every visit for ASCOT-BPLA cohort. The variance independent of mean transformation was applied if there was a correlation between the mean SBP and coefficient of variation. 10 The SBP variance independent of mean was derived for all on-treatment SBP values, analyzing total variability (within-visit and between-visit variability) using a coefficient of variation (SD/mean k ), with k determined from curve fitting. 10 Analysis also included the use of residual SD for effect size estimates, which is the square root of the total squared deviation of data points from a linear regression of BP values against time, divided by (n-2), with n being the number of readings. 10 All analyses were adjusted for age, sex, sex-age (sex×age, with gender coded as 1 [men] or 2 [women]), SBP mean, and the first 10 principal components (from decomposition of the genotype matrix).
For the stroke meta-analysis, the candidate SNPs were extracted from the genome-wide data, and site-specific logistic regression analysis was performed to test the association of top SNP with overall ischemic stroke and its major subtypes (large artery disease, cardioembolic stroke, and small vessel disease) under an additive genetic model. Age and sex were used as covariates. Beta coefficients, SEs, and P values from different studies were pooled via inverse variance meta-analysis using a fixed effects model. Meta-analysis was performed for overall ischemic stroke and its subtypes on the basis of Trial of Org 10172 in Acute Stroke Treatment criteria 23 using METAL software. 25 Pooled odds ratios (ORs) were calculated using estimated effect size of the SNP and SE of the effect size estimate. The 95% CIs were calculated using ORs and SE. A detailed description of the statistical analysis methods for each participating study is provided in Table IV in the online-only Data Supplement.
Power for the stroke meta-analysis was calculated using the CATS genetic power calculator. 26 The following parameters were used to calculate the power for the replication of SNPs rs976683 in the ischemic stroke population using an additive genetic model: n (cases): 8624, n (controls): 12 722, stroke prevalence: 7.2%, 27 rs976683 minor allele frequency: 0.25, and significance level: 0.05. The sample size provided sufficient power to detect modest effect sizes ranging from 1.1 to 1.4 for overall ischemic stroke but had reduced power for subtypes.
Results
ASCOT GWAS
The ASCOT GWAS population consisting of 3802 subjects comprised primarily men (82.3%) with a mean age of 63.7 (±8.1) years. Mean baseline SBP, mean baseline DBP, and mean variance independent of mean were 161.6 mm Hg (±17.6), 92.4 mm Hg (±9.9), and 0.004 mm Hg (±0.001), respectively. Details of the ASCOT-UK-IR study population are tabulated in Table I in the online-only Data Supplement.
GWAS for BP variability identified a cluster of 17 correlated SNPs within the Neuroligin-1 (NLGN1) gene on 3q26.31 (ENCODE ID: ENSG00000169760.13; Figure 1 ; Figure 2A and 2B). The effect size for SNP rs976683 association was small (β=0.000179), corresponding to a 0.01% mm Hg change in BP variability per copy of the risk allele. Conditional analysis using rs976683 provided no evidence of an independent signal at this locus (P=0.18).
The top genotyped SNP to reach genome-wide significance (P=1.72×10 −8 ) was rs9830510 ( Figure 2C and 2D) . The direction of effect was in concordance with rs976683; however, the SNPs were not highly correlated (r 2 =0.5; D=0.93). Despite no evidence of an additional signal from the conditional analysis, the genotyped SNP rs9830510 was also tested for association in the ischemic stroke cohort to ensure that the association result of imputed SNP rs976683 was not an imputation artifact. rs9830510 was directly genotyped in all 7 cohorts with an average minor allele frequency of 0.15 ( 
Ischemic Stroke Population Demographics
ASCOT BP Variability Follow-Up
Association testing of rs976683 with BP variability in the ASCOT Scandinavian arm provided no evidence of association (P=0.18).
Discussion
We provide evidence supporting a role of genetic variants at the Neuroligin-1 (NLGN1) locus with BP variability, but we were unable to demonstrate association between this locus and ischemic stroke and BP variability in an independent Scandinavian sample. A GWAS for BP variability in the UK-IR discovery cohort identified a cluster of 17 correlated SNPs within the NLGN1 gene that encode a neuronal cell surface protein implicated in the growth and remodeling of the vascular system. 28 The strongest association reaching genome-wide significance was at imputed SNP rs976683 (P=1.4×10 −8 ) and a correlated genotyped SNP rs9830510 (P=1.7×10 −8 ), which represents a novel locus for BP variability in hypertensives and has not been detected in any previous BP GWAS. The effect size for the sentinel association was extremely small (β=0.000179), corresponding to a 0.01% unit change in BP variability per copy of the risk allele. Similar observations have been made in GWAS of other measures of BP, in which effect sizes were also very small (1 mm Hg SBP and 0.5 mm Hg diastolic BP) but could have the potential to significantly alter the outcomes at a population level. This evidence leads us to believe that the observed effect (albeit small) may be part of a battery of unrelated and common gene loci that exert independent but small effects that compound to cause the disease. However, this hypothesis can only be confirmed via large prospective GWAS.
We attempted to replicate our findings with BP variability in 2 ways: first, testing the top SNPs for association with ischemic stroke in an independent population comprising 8624 cases and 12 722 controls from 7 cohorts. This is a common exploratory approach used to study candidate genes that may be associated with different vascular disorders, such as MI and stroke, through their effect on shared risk factors, such as hypertension, diabetes mellitus, and smoking. 29 Our sample size provided sufficient power to detect modest effect sizes ranging from 1.1 to 1.4 for overall ischemic stroke; however, as with other studies, it had reduced power for subtypes because of small sample size. SNPs rs976683 and rs9830510 were not significantly associated (P≤0.05) with the risk of overall stroke or its subtypes, with the estimated pooled ORs ranging from 1.02 to 0.96 for overall ischemic stroke, 1.07 to 1.03 for cardioembolic, 0.98 to 0.76 for large vessel disease, and 1.07 to 1.01 for small vessel disease.
The failure to detect an association with overall stroke could be because of several reasons. Genes affecting multifactorial diseases, such as stroke, usually have small effect sizes and are difficult to identify in modestly sized study populations. Insufficient statistical power, given the small observed effect size for rs976683 on BP variability, is the most likely cause of an undetectable association with ischemic stroke. Another reason could be the clinical phenotypic heterogeneity introduced because of the diverse pathogenesis of ischemic stroke, which makes it difficult to differentiate true signals from noise. Large studies, such as the recent METASTROKE 30 meta-analysis that included 15 stroke cohorts comprising 12 000 cases and 60 000 controls, also failed to identify any new genetic risk variants and only validated previous findings of variants within genes PITX2, ZFHX3, and HDAC9. Despite the large study population, the observed effect sizes were small (OR, 1.39-0.96), suggesting that a combined burden of risk alleles carried by an individual is the likely cause, as shown in hemorrhagic stroke. 31 These studies have also highlighted the subtype-specific nature of the risk, which lends support to the fact that true associations may be hidden under the multifactorial pathogenesis of stroke. Our work also has a number of limitations, which include possible inaccuracy of the Trial of Org 10172 in Acute Stroke Treatment classification into stroke subtypes. The case-control study design of our meta-analysis may be another limitation because some studies can induce survival bias by including recurrent stroke, thus allowing selection of milder forms of strokes.
The second attempt to replicate our findings included testing for association of rs976683 with BP variability in 3900 individuals from the Scandinavian arm of the ASCOT study. Although not an ideal resource for follow-up of our original observation, it was the only available replication population in which individuals were selected using identical recruitment criteria as the ASCOT-UK-IR cohort and BP measurements were performed at the same time points, allowing identical analysis of BP variability. However, replication analysis in this population provided no evidence of association between NLGN1 and BP variability (P=0.18). Failure to replicate this association may, in part, be because of population stratification induced by Anglo-Scandinavian differences, such as admixture of Finnish and central European ancestry 32 and recruitment of the ASCOT-SE samples in Sweden. There are considerable genetic differences among Europeans, and studies have demonstrated autosomal substructure in the Finnish and Swedish populations, warning researchers against making assumptions of genetic homogeneity in isolated European populations. [33] [34] [35] These studies have also shown that the British population is genetically less differentiated as compared with the Scandinavian populations. 33 Such findings have an impact on the choice of study participants for a GWAS because undetected population substructure is known to introduce bias in GWAS. 36 Furthermore, it is also possible that the genetic effect is confined to specific subpopulations of smokers, alcohol consumers, and furosemide-exposed individuals within the ASCOT-UK-IR cohort. Identified SNPs from the ASCOT-UK-IR GWAS could also be artifactual.
The power to detect the effect size of a genetic risk variant is dependent on its minor allele frequency. 37 It is interesting that the minor allele frequency of SNPs rs976683 and rs9830510 in both study populations was similar (0.25 in ASCOT-UK-IR and 0.15 in ischemic stroke cohorts). However, even though the point estimates of the effect sizes observed for stroke were larger than BP variability, no comparative conclusions could be drawn from this because neither SNP was significantly associated with the increased risk of stroke. SNPs rs976683 and rs9830510 are intronic, and an in silico-regulatory SNP detection framework 38 predicts that these SNPs alter transcription factor-binding sites for >150 cellular transcription factors. Because of the lack of association with any phenotypic trait at genome-wide significance, information regarding expression quantitative trait loci, tissue-specific expression, and histone marks remains scarce through conventional data mining resources. NLGN1 gene may play a role in BP variability via processes involving the growth and remodeling of the vascular system. 28 The NLGN1 protein ubiquitously produced outside the central nervous system and expression of its α-and β-protein isoforms in the blood vessel walls and pancreatic β-cells 39 support roles in atherosclerosis and
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insulin regulation, respectively, cellular processes that may play a role in stroke. The widespread impact of the misfiring NLGN1 gene is demonstrated in its association with type II granular corneal dystrophy 40 and autism, 41 which suggests that its effects can be mediated through varied cellular processes. To date, SNP rs976683 has only been suggestively implicated in Parkinson disease. 42 Our findings implicate SNPs at the NLGN1 locus are associated with BP variability but not ischemic stroke, although a suitable replication cohort could not be found to confirm our results. To understand the true relationship between visit-tovisit BP variability and risk of stroke, large prospective longitudinal studies after healthy cohorts for stroke occurrence are required. There is a need for international guidelines for clinical monitoring of BP variability that advocate diagnosis and assessment of treatment response in hypertension to be based on the average of a series of BP measures. Calibration of measuring devices is also needed to avoid phenotypic bias. 
Cohort description
The Anglo-Scandinavian Cardiac Outcome Trial (ASCOT) study is a longitudinal study investigating the impact of a calcium channel blocker against a beta-blocker regime in 19,342 hypertensive individuals at moderate risk of a CV outcome recruited in the United Kingdom, Ireland and Nordic countries 1 . The ASCOT Blood Pressure Lowering Arm (ASCOT-BPLA) is an investigator-led multi-centre trial which included over 19,000 hypertensive patients, aged 40-79 years at baseline, with an average SBP of 140/90 mmHg on-treatment and 160/100 mmHg off-treatment. Patients had no history of CHD but had at least three other risk factors for cardiovascular disease such as LVH, type II diabetes mellitus, peripheral artery disease, previous stroke/TIA, male, ≥ 55 years of age or cigarette smoking. The study tested the impact of a contemporary calcium channel blocker based regimen against an older beta blocker based regime in hypertensives at moderate risk of a CV outcome. The primary objective of the blood pressure-lowering arm was to assess and compare the long-term effects of two blood-pressure-lowering regimens on the combined endpoint of non-fatal myocardial infarction (including silent myocardial infarction) and fatal CHD. Visit-to-visit BP variability measurements were recorded prospectively over 5.5 years and blood pressure was measured in a seated position by a uniform automated device (Omron HEM705CP) in all participants. Genome wide association scan was performed with no a prior hypothesis about mechanism. 3802 individuals from ASCOT (UK or Irish) were genotyped on Illumina 370K array. The Analyse Variance Independent of Mean (VIM) test was performed for significance and Residual Standard Deviation (RSD) for effect size estimates.
A subset of 3,900 individuals from the ASCOT study recruited in Denmark, Finland, Norway and Sweden (ASCOT-DK-FI-NO-SE) for whom DNA was available were utilized for replication analyses. The recruitment criteria for the Scandinavian ASCOT participants were identical to the UK and Irish participants, and all had BP measurements taken at similar time-points to calculate BP variability. Table I .
Details of ASCOT-UK-IR study population are tabulated in
Genotyping and imputation
Genotyping for the ASCOT samples was performed using the Illumina Human CNV370 Bead Array. For the SNPs that were not directly genotyped, genotypes were obtained through imputation.
Single SNP genotyping of rs976683 in 3,900 Scandinavian ASCOT samples was performed using the KASPAR assay at Bart's and the London Genome Centre. Image processing and genotype calling was using SDS (Applied Biosystems) and Autocaller (Applied Biosystems). Any genotypes discrepant between the two calling algorithms was manually inspected and corrected.
Quality Control
Quality control and imputation of the ASCOT data have been described previously 2 . After stringent quality control and genotype imputation, a total of ~2.5 million SNPs and 3,802 individuals were tested for association.
5
Section 2: Ischemic stroke cohort
Cohort descriptions
The stroke population included 8,624 cases and 12,722 controls from 7 different cohorts: Australian Stroke Genetics Collaborative (ASGC) 3, 4 , Bio-Repository of DNA in Stroke (BRAINS) 5, 6 , Genetics of Early Onset Stroke (GEOS) 7, 8 , Ischemic Stroke Genetics Study and Siblings with Ischemic Stroke Study (ISGS 9 / SWISS 10 ), Welcome Trust Case Control Consortium 2 United Kingdom (WTCCC2-UK) 11 , Welcome Trust Case Control Consortium 2 Germany (WTCCC2-Germany) 11 and Vitamin Intervention for Stroke Prevention trial (VISP) 12 . All participating cohorts received institutional ethical clearance and signed consent from each participating study subject. 4 . Stroke was defined by World Health Organization criteria as a sudden focal neurological deficit of vascular origin, lasting more than 24 h and confirmed by imaging, such as computerized tomography (CT) and/or magnetic resonance imaging (MRI) brain scan. Other investigative tests such as electrocardiogram, carotid doppler and trans-esophageal echocardiogram were conducted to define ischemic stroke mechanism as clinically appropriate. Cases were excluded from participation if they were aged <18 years, were diagnosed with hemorrhagic stroke or had transient ischemic attack rather than ischemic stroke or if they were unable to undergo baseline brain imaging. On the basis of these criteria, a total of 1,230 ischemic stroke cases were included in the current study. Ischemic stroke subtypes were assigned using TOAST criteria on the basis of clinical, imaging and risk factor data. ASGC controls were participants in the Hunter Community Study (HCS), a population-based cohort of individuals aged 55-85 years, predominantly of European ancestry and residing in the Hunter Region in New South Wales, Australia. Detailed recruitment methods for the HCS have been previously described. Briefly, participants were randomly selected from the New South Wales State electoral roll and were contacted by mail between 2004 and 2007. Consenting participants completed five detailed self-report questionnaires and attended the HCS data collection center, at which time a series of clinical measures were obtained. A total of 1,280 HCS participants were genotyped for the current study. All study participants gave informed consent for participation in genetic studies. Approval for the individual studies was obtained from the relevant institutional ethics committees.
BRAINS is an ongoing, multicentre, in-hospital study which recruits consenting acute stroke patients into a highly characterized biobank 5, 6 . All adult (>18 years of age) stroke patients are recruited with either ischemic or haemorrhagic pathology MRI confirmed lesions. Ischemic stroke subtypes are further sub-classified according to TOAST criteria 13 .
Known monogenic causes of stroke are excluded. BRAINS has two principal arms. The first arm recruits UK European stroke patients while the second arm recruits South Asian stroke patients from multiple sites in the UK and also from sites in India. Control data for the European arm is provided by the Wellcome Trust Case Control Consortium while control subjects for the South Asian arm are recruited simultaneously as the affected stroke patient and usually is the proband's spouse.
For the BRAINS dataset site-specific quality control was performed in PLINK to remove individuals failing the following filters: (1) Call rate ≤ 95%, (2) GEOS is a population-based case-control study designed to identify genes associated with early-onset ischemic stroke and to characterize interactions of identified stroke genes and/or SNPs with environmental risk factors 14 Case participants were hospitalized with a first cerebral infarction identified by discharge surveillance from one of the 59 hospitals in the greater Baltimore-Washington area and direct referral from regional neurologists. The abstracted hospital records of cases were reviewed and adjudicated for ischemic stroke subtype by a pair of neurologists according to previously published procedures with disagreements resolved by a third neurologist. The ischemic stroke subtype classification system retains information on all probable and possible causes, and is reducible to the more widely used TOAST system that assigns each case to a single category. Control participants without a history of stroke were identified by randomdigit dialing and were balanced to cases by age and region of residence in each recruitment periods. Genomic DNA was isolated from a variety of sample types, including cell line, whole blood, mouth wash and buccal swab. Samples were genotyped at the Johns Hopkins Center for Inherited Disease Research (CIDR) using the Illumina HumanOmni1-Quad_v1-0_B BeadChip (Illumina, San Diego, CA, USA). Individuals were excluded if they were unexpected duplicates, gender discrepancy and unexpected relatedness.
ISGS/SWISS:
ISGS is a multicenter inception cohort study of first-ever ischemic stroke in adult men and women 9 . Cases were recruited from inpatient stroke services at five academic medical centers in Florida, Georgia, Virginia and Minnesota. The diagnosis of ischemic stroke was confirmed by a study neurologist on the basis of medical history, physical examination and CT or MR imaging of the brain. Cases had to be enrolled within 30 days of onset of stroke symptoms. Cases were excluded if they had a mechanical aortic or mitral valve, central nervous system vasculitis, or bacterial endocarditis at the time of the stroke. They were also excluded if they were known to have: cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), Fabry disease, homocystinuria, mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS), or sickle cell anemia. Stroke severity at enrollment was assessed using the NIH Stroke Scale (NIHSS) and outcomes at 90-days were assessed by telephone using the Barthel Index, Glasgow Outcome Scale, and the modified Rankin scale 15 . Diagnostic evaluation included: head CT (95% of individuals enrolled) or MRI (83%), electrocardiography (92%), cervical arterial imaging (86%), and echocardiography (74%). A vascular neurology committee reviewed the medical records of every case and assigned ischemic stroke subtype diagnoses according to criteria from the Trial of ORG10172 (TOAST) 13 , the Oxfordshire Community Stroke Project 16 , and the Baltimore-Washington Young Stroke Study 17 . DNA was donated to the NINDS DNA Repository (Coriell Institute, Camden, NJ) for eligible samples with appropriate written informed consent. A separate certified neurologist adjudicator additionally assigned a subtype diagnosis using the standardized Causative Classification of Stroke web-based algorithm 18 .
SWISS is a multicenter affected sibling pair study 19 . Probands with ischemic stroke were enrolled at 66 US medical centers and 4 Canadian medical centers. Probands are adult men and women over the age of 18 years diagnosed with ischemic stroke confirmed by a study neurologist on the basis of history, physical examination and CT or MR imaging of the brain. Probands were required to have a history of at least one living sibling with a history of stroke. Probands were excluded if they had a mechanical aortic or mitral valve, central nervous system vasculitis, or bacterial endocarditis at the time of the index ischemic stroke. Probands were also excluded if they were known to have cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), Fabry disease, homocystinuria, mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS), or sickle cell anemia. Siblings were enrolled using proband-initiated contact 20 or direct contact when permitted by Institutional Review Boards. Concordant (affected) siblings had their diagnosis of ischemic stroke confirmed by review of medical records by a vascular neurology committee. Concordant siblings had the same eligibility criteria as probands. Subtype diagnoses were assigned to the index strokes of probands and concordant siblings according to TOAST criteria 13 . Discordant siblings of the proband were confirmed to be stroke-free using the Questionnaire for Verifying Stroke-free Status 21 . Lymphoblastoid cell lines were created on all subjects. A certified neurologist adjudicator additionally assigned a subtype diagnosis using the standardized Causative Classification of Stroke web-based algorithm to all concordant siblings and a subset of probands for whom medical records were available 18 .
VISP:
The VISP trial (P.I. James Toole, MD, Wake Forest University School of Medicine (WFU); R01 NS34447) was a multi-center, A subset of VISP participants gave consent and were included in the GWAS component of VISP, supported by the National Human Genome Research Institute (NHGRI), Grant U01 HG005160, as part of the Genomics and Randomized Trials Network (GARNET). Samples were genotyped at the Johns Hopkins Center for Inherited Disease Research (CIDR), and genotyping was performed using the Illumina HumanOmni1-Quad_v1-0_B BeadChip (Illumina, San Diego, CA, USA). Individuals were excluded if they were unexpected duplicates or had gender discrepancies. All VISP participants are stroke cases, therefore we obtained GWAS data (dbGAP) for 1047 external controls from the High Density SNP Association Analysis of Melanoma: Case-Control and Outcomes Investigation (Study Accession: phs000187.v1.p1). These samples were also genotyped on the Illumina HumanOmni1-Quad.
WTCCC2-United Kingdom and WTCCC2-Germany
The WTCCC2 samples were genotyped as part of the WTCCC 2 ischemic stroke study 11 . Stroke cases included samples recruited by investigators at St. George's University London (SGUL), University of Oxford and Edinburgh Stroke Study in the UK and the Department of Neurology, Klinikum Großhadern, Ludwig-Maximilians-University, Munich. The SGUL collection comprised 1224 ischemic stroke samples from a hospital based setting. All cases were of self-reported Caucasian ancestry. Ischemic stroke subtypes were determined according to TOAST criteria based on relevant clinical imaging and available information on cardiovascular risk factors. The University of Oxford collection comprised 896 ischemic stroke cases, consecutively collected as part of the Oxford vascular study (OXVASC). Cases were of self-reported Caucasian ancestry, and ischemic stroke subtypes were determined according to TOAST criteria based on relevant clinical imaging. For the Edinburgh Stroke Study, consecutive consenting patients with stroke who were admitted to or seen as outpatients at the Western General Hospital, Edinburgh were prospectively recruited between 2002 and 2005.
Cases in this study were those with a clinically evident stroke, demonstrated by brain imaging (CT or MRI) to be ischemic. An experienced stroke physician assessed each patient as soon as possible after the stroke, prospectively recording demographic and clinical details, including vascular risk factors and results of brain imaging and other investigations. The Munich samples included 1383 ischemic stroke cases. Cases were consecutive European Caucasians recruited from a single dedicated Stroke Unit at the Department of Neurology, Klinikum Großhadern, Ludwig-Maximilians-University, Munich. Ischemic stroke subtypes were determined according to TOAST criteria based on relevant clinical and imaging data. Controls for the UK samples were drawn from shared WTCCC controls obtained from the 1958 Birth Cohort. This is a prospectively collected cohort of individuals born in 1958 (http://www.b58cgene.sgul.ac.uk/), and ascertained as part of the national child development study (http://www.cls.ioe.ac.uk/studies.asp). Data from this cohort are available as a common control set for a number of genetic and epidemiological studies. For the German samples controls were Caucasians of German origin participating into the population KORAgen study (www.gsf.de/kora). This survey represents a gender-and age stratified random sample of all German residents of the Augsburg area and consists of individuals 25 to 74 years of age, with about 300 subjects for each 10-year increment. All controls were free of a history of stroke or transient ischemic attack.
Wellcome Trust Case-Control Consortium 2 (WTCCC2) -Genotyping
All WTCCC2 cases were genotyped as part of the WTCCC2 Ischemic Stroke study using the Illumina Human660W-Quad array. British controls were genotyped using the Illumina Human1.2M-Duo. German controls were genotyped on the Illumina Human 550k platform. Quality control procedures in the WTCCC2 excluded SNPs not genotyped on all case and control collections and SNPs with Fisher information measure <0.98, genotype call rate <0.95, MAF <0.01 or Hardy-Weinberg P-value <1×10-20 in either the case or control collections. Samples were excluded if identified as outliers on call rate, heterozygosity, ancestry and average probe intensity based on a Bayesian clustering algorithm. Samples were also removed if they exhibited discrepancies between inferred and recorded gender or cryptic relatedness with other WTCCC2 samples (pairwise identity-by-descent >0.05). Autosomal genotype imputation was performed using MACH based on HapMap Phase 2 European (CEU) reference data. Tables   Table I. Effect sizes are shown as odds ratios for the % increase or decrease per copy of the risk allele. N (number of individuals) Q (Chi square statistics), I 2 (Index test quantifies extent of variation across studies in a meta-analysis), OR (Odds Ratio), CI (confidence interval), p (probability value), CE (Cardio-embolic stroke), LVD (Large Vessel Disease), SVD (Small Vessel Disease) Effect sizes are shown as odds ratios for the % increase or decrease per copy of the risk allele. N (number of individuals) Q (Chi square statistics), I 2 (Index test quantifies extent of variation across studies in a meta-analysis), OR (Odds Ratio), CI (confidence interval), p (probability value), CE (Cardio-embolic stroke), LVD (Large Vessel Disease), SVD (Small Vessel Disease)
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